Spectrum Pharmaceuticals Inc. (SPPI) Climbed On Phase 3 Study Results

Spectrum Pharmaceuticals Inc. (SPPI) announced after the bell Wednesday that its Phase 3 study of Rolontis met its primary endpoint and all secondary endpoints.

from RTT - Before the Bell https://ift.tt/2IuunJT
via IFTTT